ArticleNature communications2024
Concomitant medication, comorbidity and survival in patients with breast cancer.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Impact of statin use on survival and adverse events in patients with cancer receiving radiotherapy: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics.British journal of cancer · 2025Pooled it
- Cardiovascular Events Associated with CDK4/6 Inhibitors: A Safety Meta-Analysis of Randomized Controlled Trials and a Pharmacovigilance Study of the FAERS Database.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Pooled it
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors.Cancer chemotherapy and pharmacology · 2026Review
- Global longitudinal strain decline after anthracyclines in a relatively low-risk Japanese breast cancer cohort.Heart and vessels · 2026Article
- Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort.Med (New York, N.Y.) · 2026Article
- Observational
- Sexual dysfunction in Brazilian women undergoing adjuvant endocrine therapy for breast cancer: prevalence and associated factors.Scientific reports · 2026Article
- Clinical practice guidelines for prognosis and follow-up of early-stage breast cancer patients: Chinese Society of Breast Surgery (CSBrS) practice guidelines (2026 edition) Chinese Society of Breast Surgery, Chinese Society of Surgery, Chinese Medical Association.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Factors Associated with Potentially Inappropriate Prescribing in Patients with Prostate Cancer.Journal of clinical medicine · 2025Article
- In vitro Evaluation of Mitochondrial-Targeted Andrographolide Nanoparticles Against 4T1 Breast Cancer Cells.International journal of nanomedicine · 2025Article
- Effects of dietary habits and catheterization type on breast cancer-related lymphedema: a retrospective cohort study.BMC cancer · 2024Article
- Unveiling the comorbidity burden of male breast cancer.Scientific reports · 2024Observational
- Concomitant medication, comorbidity and survival in patients with breast cancer.Nature communications · 2024Article
- Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 1 country.
Funding
Abstract
Between 30% and 70% of patients with breast cancer have pre-existing chronic conditions, and more than half are on long-term non-cancer medication at the time of diagnosis. Preliminary epidemiological evidence suggests that some non-cancer medications may affect breast cancer risk, recurrence, and survival. In this nationwide cohort study, we assessed the association between medication use at breast cancer diagnosis and survival. We included 235,368 French women with newly diagnosed non-metastatic breast cancer. In analyzes of 288 medications, we identified eight medications positively associated with either overall survival or disease-free survival: rabeprazole, alverine, atenolol, simvastatin, rosuvastatin, estriol (vaginal or transmucosal), nomegestrol, and hypromellose; and eight medications negatively associated with overall survival or disease-free survival: ferrous fumarate, prednisolone, carbimazole, pristinamycin, oxazepam, alprazolam, hydroxyzine, and mianserin. Full results are available online from an interactive platform ( https://adrenaline.curie.fr ). This resource provides hypotheses for drugs that may naturally influence breast cancer evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.